Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas

Hepato-Gastroenterology

Volumn 55, Issue 86-87, 2008, Pages 1824-1829

  Shirai, Yoshihiko ^a   Sagawa, Kazuyuki ^a   Yamaguchi, Taketo ^a   Sudo, Kentaro ^a   Nakagawa, Akihiko ^a   Sakai, Yuji ^a   Ishihara, Takeshi ^a   Sunaga, Masahiko ^a   Nezu, Masahiko ^a   Tomonaga, Takeshi ^a   Miyazaki, Masaru ^a   Saisho, Hiromitsu ^a   Nomura, Fumio ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Intraductal papillary mucinous neoplasm of the pancreas; Pancreatic secretory trypsin inhibitor; ProteinChip; Surface enhanced laser desorption and ionization

Indexed keywords

APROTININ;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PANCREAS JUICE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RADIOIMMUNOASSAY; REFERENCE VALUE; SAMPLING; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADENOCARCINOMA, MUCINOUS; AMINO ACID SEQUENCE; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CARRIER PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 57049181361     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Maire F, Hammel P, Terris B, Paye F, Scoazee JY, Cellier C, Barthet M, O'Toole D, Rufat P, Partensky C, Cuillerier E, Levy P, Belghiti J, Ruszniewski P: Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002; 51:717-722.
2. Warshaw AL, Compton CC, Lewandrowski K, Cardenosa G, Mueller PR: Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients. Ann Surg 1990; 212:432-443.
3. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck.A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64:5882-5890.
4. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD: Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 2005; 51:695-707.
5. Sauter ER, Zhu W, Fan XJ, Wassell RP, Chervoneva I, Du Bois GC: Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 2002; 86:1440-1443.
6. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE: Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003; 63:6971-6983.
7. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright Jr GL Jr: Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158:1491-1502.
8. Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, Lee CC, Leung TW, Ho SK, Johnson PJ: Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003; 49:752-760.
9. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, Chan DW, Canto M, Lillemoe KD, Cameron JL, Yeo CJ, Hruban RH, Goggins M: Identification of hepatocarcinoma-intestine-pancreas/ pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62:1868-1875.
10. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10:860-868.
11. Bhattacharyya S, Siegel ER, Petersen GM, Chari ST, Suva LJ, Haun RS: Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 2004; 6:674-686.
12. Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, Zhang WH, Peng CH, Zhang SD, LiHW, Chen GQ: Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 2005; 68:79-86.
13. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, Wright GL Jr, Semmes OJ: Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004; 10:1625-1632.
14. Melle C, Ernst G, Schimmel B, Bleul A, Thieme H, Kaufmann R, Mothes H, Settmacher U, Claussen U, Halbhuber KJ, Von Eggeling F: Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005; 129:66-73.
15. Dayal B, Ertel NH: ProteinChip technology: a new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease. J Proteome Res 2002; 1:375-380.
16. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, Jacks K, Smith C, Kireeva I, Zhang R, Takahashi M, Stanton E, Jackowski G: Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003; 2:361-372.
17. Nomura F, Tomonaga T, Sogawa K, Ohashi T, Nezu M, Sunaga M, Kondo N, Iyo M, Shimada H, Ochiai T: Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ ionization-mass spectrometry. Proteomics 2004; 4:1187-1194.
18. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, Otto M, Kornhuber J, Wiltfang J: Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry 2004; 55:524-530.
19. Uchida T, Fukawa A, Uchida M, Fujita K, Saito K: Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002; 1:495-499.
20. Sato K, Sasaki K, Akiyama Y, Yamaguchi K: Mass spectrometric high-throughput analysis of serum-free conditioned medium from cancer cell lines. Cancer Lett 2001; 170:153-159.
21. Pubols MH, Bartelt DC, Greene LJ: Trypsin inhibitor from human pancreas and pancreatic juice. J Biol Chem 1974; 249:2235-2242.
22. Stenman UH, Huhtala ML, Koistinen R, Seppala M: Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 1982; 30:53-57.
23. Freeman TC, Playford RJ, Quinn C, Beardshall K, Poulter L, Young J, Calam J: Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice. Gut 1990; 31:1318-1323.
24. Halila H, Huhtala ML, Schroder T, Kiviluoto T, Stenman UH: Pancreatic secretory trypsin inhibitor-like immunoreactivity in pancreatectomized patients. Clin Chim Acta 1985; 153:209-216.
25. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E: Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. J Cancer Res Clin Oncol 1994; 120:494-497.
26. Satake K, Inui A, Sogabe T, Yoshii Y, Nakata B, Tanaka H, Chung YS, Hiura A, Umeyama K: The measurement of serum immunoreactive pancreatic secretory trypsin inhibitor in gastrointestinal cancer and pancreatic disease. Int J Pancreatol 1988; 3:323-331.
27. Solakidi S, Dessypris A, Stathopoulos GP, Androulakis G, Sekeris CE: Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha 1-antitrypsin in patients with gastrointestinal malignancies. Clin Biochem 2004; 37:56-60.
28. Lukkonen A, Lintula S, von Boguslawski K, Carpen O, Ljungberg B, Landberg G, Stenman UH: Tumour-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer 1999; 83:486-490.
29. Huhtala ML, Kahanpaa K, Seppala M, Halila H, Stenman UH: Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy. Int J Cancer 1983; 31:711-714.
30. Stenman UH: Tumor-associated trypsin inhibitor. Clin Chem 2002; 48:1206-1209.
31. Halila H, Huhtala ML, Haglund C, Nordling S, Stenman UH: Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer 1987; 56:153-156.
32. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M, Ylikorkala O: Tumour-associated trypsin inhibitor (TATI): comparison with CA 125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 1994; 70:1188-1190.
33. Kelloniemi E, Rintala E, Finne P, Stenman UH; Finnbladder Group: Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 2003; 62:249-253.
34. Wikstein JP, Lundin J, Nordling S, Kokkola A, Stenman UH, Haglund C: High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology 2005; 46:380-388.
35. Jarvisalo J, Hakama M, Knekt P, Stenman UH, Leino A, Teppo L, Maatela J, Aromaa A: Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. Cancer 1993; 71:1982-1988.
36. Haglund C, Huhtala ML, Halila H, Nordling S, Roberts PJ, Scheinin TM, Stenman UH: Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer 1986; 54:297-303.
37. Raty S, Sand J, Alfthan H, Haglund C, Nordback I: Cyst fluid tumor-trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions. J Gastrointest Surg 2004; 8:569-574.
38. Kawai M, Uchiyama K, Tani M, Onishi H, Kinoshita H, Ueno M, Hama T, Yamaue H: Clinicopathological features of malignant intraductal papillary mucinous tumors of the pancreas: the differential diagnosis from benign entities. Arch Surg 2004139:188-192.